BACKGROUND

Autifony is a cutting-edge biotech company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform. Since its formation in 2011, Autifony has delivered three candidate molecules into clinical development. The Company’s pipeline includes clinical stage Kv3 modulators for Fragile X and rare epilepsy syndromes. Earlier stage programmes on other voltage- and ligand-gated channels, including lysosomal ion channels, are aligned with CNS indications such as epilepsy, Parkinson’s and Alzheimer’s disease, vascular dementia and lysosomal storage disorders.
Autifony is based at the Stevenage Bioscience Catalyst in the UK (www.autifony.com).
Looking to expand its medicinal chemistry team, Autifony is seeking a self-motivated, creative, and enthusiastic individual to become part of a dynamic preclinical R&D group.

Please refer the Job description for details